SecBot SecBot

IONS

IONIS PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· Inc. CA· CIK 0000874015 Biotech & Drug Discovery
$29.06 +1.75 (+6.41%)
Nov 13 4:00 PM ET · prev $27.31
Market cap
$4.5B
Mid cap
Consensus
Buy
84% Buy or better · 32 analysts
Median target
$70.00
+141% · range $41.00–105.00
1 year
−60.3%
from $73.26 · Nov 17
30 days
−34.5%
from $44.38
52-week range
$27.31–86.50
−66% from high · low Nov 12
Avg volume 20D
4.60M
Nov 9 spike 19.50M
Short interest
21.17M
≈12.7% of shares · +2.5%
Days to cover
8.4
at average volume
Insider net
−$11.7M
1 buyer · 10 sellers · since Jun 25
New fund stakes
1
Q3 2026 13F · 4 exits
Filing reports
26
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 2 bearish · 4 bullish · 2 mixed oldest → newest, height = score
Avg score ·High conf. 6/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $1.2M at an average $48.28. 10 insiders sold $12.9M. Price is 40% below their cost.

  • InstitutionsMIXED

    Q3 2026: 44 added (1 new), 39 trimmed or exited.

  • AnalystsBULLISH

    27 of 32 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +2.5% to 21.17M shares. 8.4 days to cover, ≈12.7% of shares.

  • TrendDOWNTREND

    33% below its 50-day average. New closing low $27.31 on Nov 12.

Who's buying

13F· Q3 2026
1
new positions
4
exits
FundMoveSharesValue
STATE STREET CORPADD5,710,900$255.0M
MORGAN STANLEYDOUBLED3,143,945$140.4M
WESTFIELD CAPITAL MANAGEMENT CO LPDOUBLED2,399,864$107.2M
Qube Research & Technologies LtdDOUBLED1,995,683$89.1M
UBS Group AGDOUBLED1,508,334$67.3M
AMERICAN CENTURY COMPANIES INCTRIM1,157,694$51.7M
Squarepoint Ops LLCDOUBLED1,123,262$50.2M
JPMORGAN CHASE & COTRIM975,886$45.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

32 analysts
Buy 84% rate it Buy or better
Strong Buy8Buy19Hold5Sell0Strong Sell0
12-month targets · 23 analysts

Price is below the lowest target. Median implies +141%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Goldman Sachs
MAINTAIN
MAINTAINNeutral
Nov 10, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 10, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Nov 10, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Nov 10, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Nov 10, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$1.2M
bought · 1 insider
$12.9M
sold · 10 insiders
−39.8%
vs their $48.28 cost
DateInsiderTypeValue
Nov 10, 2026
Hayden Michael R
Director
Nov 10, 2026
BUY$148.2K
Oct 16, 2026
Swayze Eric
EVP Research
Oct 16, 2026
SELL$2.3K
Oct 16, 2026
Devers Shannon L.
EVP, Chief Human Resources Ofc
Oct 16, 2026
SELL$59.1K
Oct 15, 2026
Swayze Eric
EVP Research
Oct 15, 2026
EXERCISE125 sh
Oct 15, 2026
Devers Shannon L.
EVP, Chief Human Resources Ofc
Oct 15, 2026
EXERCISE2,820 sh
Aug 31, 2026
O'NEIL PATRICK R.
EVP CLO & General Counsel
Aug 31, 2026
OTHER$3.2K
Aug 31, 2026
Birchler Brian
EVP, Corp and Development Ops
Aug 31, 2026
OTHER$3.0K
Aug 31, 2026
Monia Brett P
Chief Executive Officer
Aug 31, 2026
OTHER$5.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

16 lobbying filings and 8 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
21,165,846
shares short
+2.5%
vs prior settlement
8.4
days to cover
≈12.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 Insider
Hayden Michael R bought 5,000 shares
Director @ $29.64 ($148.2K)
Nov 9, 2026 Other
Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ionis Pharmaceuticals (IONS)
Ionis told investors in July that TRYNGOLZA was "on track" for $100 million to $110 million in 2026
Nov 9, 2026 SEC
Total revenue, DAWNZERA guidance, operating loss and cash guidance were reaffirmed.
8-K · Impact 6/10
Oct 27, 2026 SEC
In Q2 2026, 45 institutional buyers accumulated $162.9M in IONS while 32 sellers reduced holdings by $105.9M…
INST-CLUSTER · Impact 4/10
Oct 23, 2026 SEC
Ionis partner Roche announced positive Phase 3 IMAgINATION data for sefaxersen in IgA nephropathy, showing a…
8-K · Impact 7/10
Oct 16, 2026 Insider
Swayze Eric sold 53 shares
EVP Research @ $43.54 ($2.3K)
Oct 16, 2026 Insider
Devers Shannon L. sold 1,357 shares
EVP, Chief Human Resources Ofc @ $43.54 ($59.1K)
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
5,710,900 shares ($255.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
6 drugs tracked · Drug pipeline →
Recent

SecBot reports

26 filings · 7 bullish · 3 bearish · 3 mixed · 13 neutral
All IONS filing & press-release reports (26)